John R. White
Research Subjects
Research Interests
John R. White has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Adi Kozminsky-Atias
Ferring Be’er Tuvia Industrial Zone, Kiryat Malachi, 8310402, Israel
1 shared publication - Andrew S. Thomson
Temple University Lewis Katz School of Medicine 2 Department of Medical Genetics and Molecular Biochemistry Philadelphia, PA, USA
1 shared publication - Anis Bousbia-Salah
Department of Mechanical and Nuclear Engineering, University of Pisa, Italy
1 shared publication Areeya Jirapongmed
University of Massachusetts, Department of Chemical and Nuclear Engineering, Lowell, USA, DIMNP - University of Pisa, Italy
1 shared publication- Charles S. Hottenstein
Bioanalysis, Immunogenicity, and Biomarkers, In Vitro/In Vivo Translation, GlaxoSmithKline , Collegeville, PA 19426
1 shared publication David C. Underwood/Surname
Departments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USA
1 shared publication
Latest Publications
- Open Access
- 9 February 2024
- Published by Taylor & Francis in BioTechniques
- Vol. 76 (4) , 135-144
An Industry Perspective Approach and Control Strategy for Implementation of Ready-to-Use Cells in Bioassays: Survey Outcome And Recommendations
The BioPhorum Development Group is an industry collaboration enabling the sharing of common practices for the development of biopharmaceuticals. Bioassays are an important part of an analytical con... Method summary Draft questions were composed by the authors based on prior knowledge of the issues associated with ready-to-use cell use. Questions were further refined through open discussion amon...
- 9 February 2024
- Published by Taylor & Francis in BioTechniques
- Vol. 76 (4) , 135-144
Open AccessAn Industry Perspective Approach and Control Strategy for Implementation of Ready-to-Use Cells in Bioassays: Survey Outcome And Recommendations
The BioPhorum Development Group is an industry collaboration enabling the sharing of common practices for the development of biopharmaceuticals. Bioassays are an important part of an analytical con... Method summary Draft questions were composed by the authors based on prior knowledge of the issues associated with ready-to-use cell use. Questions were further refined through open discussion amon...
- Open Access
- 28 August 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (4) , 101136
Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P
- 28 August 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (4) , 101136
Open AccessNovel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P
- 1 March 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (5) , 1067-1076
Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity
MAbs have revolutionized the treatment of autoimmune disorders. Even though mAbs have shown impressive efficacy in blocking T cell or B cell activation and/or recruitment to sites of inflammation, this group of biologicals are not devoid of adverse effects. The most serious adverse effects include infusion reactions, including the activation of the complement pathway. In this study, we present a detailed structure–function study of an anti-CCL20 humanized IgG1 mAb that neutralizes CCL20 chemokine and prevents the recruitment of Th17 cells to sites of inflammation. We demonstrate that the anti-CCL20 Ab changes significantly following administration to humans and monkeys and exposure to human serum. Analysis of the drug product revealed that the anti-CCL20 Ab has unexpectedly high C1q binding. This high binding was linked to immune complex formation in vivo but not during in vitro serum incubation. The immune complex contained multiple complement components. Anti-CCL20 Ab-mediated, complement-dependent cytotoxicity occurred when the Ab bound to CCL20 tethered to the cell membrane of target cells. Taken together, these results provide a likely cause for the animal toxicity observed. In addition, anti-CCL20 revealed progressive acidification because of N100 (located in CDR) deamidation over time, which did not directly impact Ag binding. Our study demonstrates that the safety profiling of mAbs should include the evaluation of effector functions in addition to typical stressed conditions.
- 1 March 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (5) , 1067-1076
Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity
MAbs have revolutionized the treatment of autoimmune disorders. Even though mAbs have shown impressive efficacy in blocking T cell or B cell activation and/or recruitment to sites of inflammation, this group of biologicals are not devoid of adverse effects. The most serious adverse effects include infusion reactions, including the activation of the complement pathway. In this study, we present a detailed structure–function study of an anti-CCL20 humanized IgG1 mAb that neutralizes CCL20 chemokine and prevents the recruitment of Th17 cells to sites of inflammation. We demonstrate that the anti-CCL20 Ab changes significantly following administration to humans and monkeys and exposure to human serum. Analysis of the drug product revealed that the anti-CCL20 Ab has unexpectedly high C1q binding. This high binding was linked to immune complex formation in vivo but not during in vitro serum incubation. The immune complex contained multiple complement components. Anti-CCL20 Ab-mediated, complement-dependent cytotoxicity occurred when the Ab bound to CCL20 tethered to the cell membrane of target cells. Taken together, these results provide a likely cause for the animal toxicity observed. In addition, anti-CCL20 revealed progressive acidification because of N100 (located in CDR) deamidation over time, which did not directly impact Ag binding. Our study demonstrates that the safety profiling of mAbs should include the evaluation of effector functions in addition to typical stressed conditions.
- Open Access
- 1 January 2006
- Published by National Library of Serbia in Nuclear Technology and Radiation Protection
- Vol. 21 (1) , 3-12
Assessment of RELAP5 model for the University of Massachusetts Lowell Research Reactor
RELAP5 is a system code developed at the Idaho National Environmental and Engineering Laboratory for thermal hydraulic analysis of nuclear reactors. The code RELAP5 is widely used for safety analysis studies of commercial nuclear power plants. However, recent released version of RELAP5/3.2 and over present significant capabilities for analysis of nuclear reactor research systems. As a contribution to the assessment of RELAP5/3.3 for research reactor safety analysis, experimental data from the University of Massachusetts Lowell Research Reactor - UMLRR are used. The UMLRR is a 1 MW light water moderated and cooled, graphite-reflected, open-pool type research reactor. This paper presents the development and the validation of a UMLRR-RELAP model using experimental data. For this purpose, a series of experiments were performed for benchmarking RELAP5 calculations for research reactor systems. As a result of this study, the UMLRR nodalization is shown to be representative of the experimental data reactor behavior.
- 1 January 2006
- Published by National Library of Serbia in Nuclear Technology and Radiation Protection
- Vol. 21 (1) , 3-12
Open AccessAssessment of RELAP5 model for the University of Massachusetts Lowell Research Reactor
RELAP5 is a system code developed at the Idaho National Environmental and Engineering Laboratory for thermal hydraulic analysis of nuclear reactors. The code RELAP5 is widely used for safety analysis studies of commercial nuclear power plants. However, recent released version of RELAP5/3.2 and over present significant capabilities for analysis of nuclear reactor research systems. As a contribution to the assessment of RELAP5/3.3 for research reactor safety analysis, experimental data from the University of Massachusetts Lowell Research Reactor - UMLRR are used. The UMLRR is a 1 MW light water moderated and cooled, graphite-reflected, open-pool type research reactor. This paper presents the development and the validation of a UMLRR-RELAP model using experimental data. For this purpose, a series of experiments were performed for benchmarking RELAP5 calculations for research reactor systems. As a result of this study, the UMLRR nodalization is shown to be representative of the experimental data reactor behavior.